Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins

Cell Reports

Volumn 14, Issue 11, 2016, Pages 2587-2598

  Kitange, Gaspar J ^a   Mladek, Ann C ^a   Schroeder, Mark A ^a   Pokorny, Jenny C ^a   Carlson, Brett L ^a   Zhang, Yuji ^a,c   Nair, Asha A ^a   Lee, Jeong Heon ^b   Yan, Huihuang ^a   Decker, Paul A ^a   Zhang, Zhiguo ^b   Sarkaria, Jann N ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; MGMT; RBBP4; Resistance; Temozolomide

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; HISTONE H2AX; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RAD51 PROTEIN; RETINOBLASTOMA BINDING PROTEIN 4; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; E1A ASSOCIATED P300 PROTEIN; EP300 PROTEIN, HUMAN; HISTONE; RAD51 PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; EPIGENETICS; GENE EXPRESSION; GLIOBLASTOMA; MGMT GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAD51 GENE; ACETYLATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DACARBAZINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA DAMAGE; E1A-ASSOCIATED P300 PROTEIN; GLIOBLASTOMA; HISTONES; HUMANS; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RAD51 RECOMBINASE; REAL-TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA-BINDING PROTEIN 4; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84959907090     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.045     Document Type: Article

References (50)

1. Bhakat K.K., Mitra S. Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. J. Biol. Chem. 2000, 275:34197-34204.
2. Cahill D.P., Codd P.J., Batchelor T.T., Curry W.T., Louis D.N. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin. Neurosurg. 2008, 55:165-171.
3. Carlson B.L., Pokorny J.L., Schroeder M.A., Sarkaria J.N. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr. Protoc. Pharmacol. 2011, Chapter 14:Unit 14.16.
4. Chai K.M., Wang C.Y., Liaw H.J., Fang K.M., Yang C.S., Tzeng S.F. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Oncotarget 2014, 5:10901-10915.
5. Clark C.C., Weitzel J.N., O'Connor T.R. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol. Cancer Ther. 2012, 11:1948-1958.
6. Cook P.J., Ju B.G., Telese F., Wang X., Glass C.K., Rosenfeld M.G. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009, 458:591-596.
7. Dedes K.J., Wilkerson P.M., Wetterskog D., Weigelt B., Ashworth A., Reis-Filho J.S. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011, 10:1192-1199.
8. Drabløs F., Feyzi E., Aas P.A., Vaagbø C.B., Kavli B., Bratlie M.S., Peña-Diaz J., Otterlei M., Slupphaug G., Krokan H.E. Alkylation damage in DNA and RNA--repair mechanisms and medical significance. DNA Repair (Amst.) 2004, 3:1389-1407.
9. Fiskus W., Sharma S., Qi J., Shah B., Devaraj S.G., Leveque C., Portier B.P., Iyer S., Bradner J.E., Bhalla K.N. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol. Cancer Ther. 2014, 13:2315-2327.
10. Fiskus W., Sharma S., Qi J., Valenta J.A., Schaub L.J., Shah B., Peth K., Portier B.P., Rodriguez M., Devaraj S.G., et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol. Cancer Ther. 2014, 13:1142-1154.
11. Furuyama T., Dalal Y., Henikoff S. Chaperone-mediated assembly of centromeric chromatin in vitro. Proc. Natl. Acad. Sci. USA 2006, 103:6172-6177.
12. Gaspar N., Marshall L., Perryman L., Bax D.A., Little S.E., Viana-Pereira M., Sharp S.Y., Vassal G., Pearson A.D., Reis R.M., et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res. 2010, 70:9243-9252.
13. Hegi M.E., Diserens A.C., Godard S., Dietrich P.Y., Regli L., Ostermann S., Otten P., Van Melle G., de Tribolet N., Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 2004, 10:1871-1874.
14. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
15. Hirose Y., Berger M.S., Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001, 61:1957-1963.
16. Hirose Y., Kreklau E.L., Erickson L.C., Berger M.S., Pieper R.O. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J. Neurosurg. 2003, 98:591-598.
17. Kitange G.J., Carlson B.L., Mladek A.C., Decker P.A., Schroeder M.A., Wu W., Grogan P.T., Giannini C., Ballman K.V., Buckner J.C., et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J. Neurooncol. 2009, 92:23-31.
18. Kitange G.J., Carlson B.L., Schroeder M.A., Grogan P.T., Lamont J.D., Decker P.A., Wu W., James C.D., Sarkaria J.N. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncol. 2009, 11:281-291.
19. Kitange G.J., Carlson B.L., Schroeder M.A., Decker P.A., Morlan B.W., Wu W., Ballman K.V., Giannini C., Sarkaria J.N. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J. Neurooncol. 2010, 100:177-186.
20. Kitange G.J., Mladek A.C., Carlson B.L., Schroeder M.A., Pokorny J.L., Cen L., Decker P.A., Wu W., Lomberk G.A., Gupta S.K., et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin. Cancer Res. 2012, 18:4070-4079.
21. Knoechel B., Roderick J.E., Williamson K.E., Zhu J., Lohr J.G., Cotton M.J., Gillespie S.M., Fernandez D., Ku M., Wang H., et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 2014, 46:364-370.
22. Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P., Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002, 16:2893-2905.
23. Liu X., Han E.K., Anderson M., Shi Y., Semizarov D., Wang G., McGonigal T., Roberts L., Lasko L., Palma J., et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol. Cancer Res. 2009, 7:1686-1692.
24. Ogiwara H., Kohno T. CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes. PLoS ONE 2012, 7:e52810.
25. Pan M.R., Hsieh H.J., Dai H., Hung W.C., Li K., Peng G., Lin S.Y. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment. J. Biol. Chem. 2012, 287:6764-6772.
26. Ramos Y.F., Hestand M.S., Verlaan M., Krabbendam E., Ariyurek Y., van Galen M., van Dam H., van Ommen G.J., den Dunnen J.T., Zantema A., 't Hoen P.A. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res. 2010, 38:5396-5408.
27. Roos W.P., Nikolova T., Quiros S., Naumann S.C., Kiedron O., Zdzienicka M.Z., Kaina B. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst.) 2009, 8:72-86.
28. Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 2008, 14:2900-2908.
29. Short S.C., Giampieri S., Worku M., Alcaide-German M., Sioftanos G., Bourne S., Lio K.I., Shaked-Rabi M., Martindale C. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro-oncol. 2011, 13:487-499.
30. Stark J.M., Hu P., Pierce A.J., Moynahan M.E., Ellis N., Jasin M. ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair. J. Biol. Chem. 2002, 277:20185-20194.
31. Stucki M. Histone H2A.X Tyr142 phosphorylation: a novel sWItCH for apoptosis?. DNA Repair (Amst.) 2009, 8:873-876.
32. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials GroupNational Cancer Institute of Canada Clinical Trials Group.
33. Tang Y., Gholamin S., Schubert S., Willardson M.I., Lee A., Bandopadhayay P., Bergthold G., Masoud S., Nguyen B., Vue N., et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 2014, 20:732-740.
34. Tentori L., Ricci-Vitiani L., Muzi A., Ciccarone F., Pelacchi F., Calabrese R., Runci D., Pallini R., Caiafa P., Graziani G. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer 2014, 14:151.
35. Todd M.A., Picketts D.J. PHF6 interacts with the nucleosome remodeling and deacetylation (NuRD) complex. J. Proteome Res. 2012, 11:4326-4337.
36. Torres-Roca J.F., Eschrich S., Zhao H., Bloom G., Sung J., McCarthy S., Cantor A.B., Scuto A., Li C., Zhang S., et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 2005, 65:7169-7176.
37. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
38. Venneti S., Garimella M.T., Sullivan L.M., Martinez D., Huse J.T., Heguy A., Santi M., Thompson C.B., Judkins A.R. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 2013, 23:558-564.
39. Vermaak D., Wade P.A., Jones P.L., Shi Y.B., Wolffe A.P. Functional analysis of the SIN3-histone deacetylase RPD3-RbAp48-histone H4 connection in the Xenopus oocyte. Mol. Cell. Biol. 1999, 19:5847-5860.
40. Vlachostergios P.J., Hatzidaki E., Papandreou C.N. MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53. Neurol. Res. 2013, 35:879-882.
41. Wilting R.H., Dannenberg J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updat. 2012, 15:21-38.
42. Wolffe A.P., Urnov F.D., Guschin D. Co-repressor complexes and remodelling chromatin for repression. Biochem. Soc. Trans. 2000, 28:379-386.
43. Yan G., Eller M.S., Elm C., Larocca C.A., Ryu B., Panova I.P., Dancy B.M., Bowers E.M., Meyers D., Lareau L., et al. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J. Invest. Dermatol. 2013, 133:2444-2452.
44. Yarden R.I., Brody L.C. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. USA 1999, 96:4983-4988.
45. Yip S., Miao J., Cahill D.P., Iafrate A.J., Aldape K., Nutt C.L., Louis D.N. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 2009, 15:4622-4629.
46. Yoshimoto K., Mizoguchi M., Hata N., Murata H., Hatae R., Amano T., Nakamizo A., Sasaki T. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front. Oncol. 2012, 2:186.
47. Yuan J., Chen J. FIGNL1-containing protein complex is required for efficient homologous recombination repair. Proc. Natl. Acad. Sci. USA 2013, 110:10640-10645.
48. Zhang Q., Vo N., Goodman R.H. Histone binding protein RbAp48 interacts with a complex of CREB binding protein and phosphorylated CREB. Mol. Cell. Biol. 2000, 20:4970-4978.
49. Zhang N., Wu X., Yang L., Xiao F., Zhang H., Zhou A., Huang Z., Huang S. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin. Cancer Res. 2012, 18:5961-5971.
50. Zhang W., Tyl M., Ward R., Sobott F., Maman J., Murthy A.S., Watson A.A., Fedorov O., Bowman A., Owen-Hughes T., et al. Structural plasticity of histones H3-H4 facilitates their allosteric exchange between RbAp48 and ASF1. Nat. Struct. Mol. Biol. 2013, 20:29-35.